drugset / Trial / NCT02214381
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with increased risk of relapse.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-10
- Completion
- 2025-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | — |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | — |